12/25
08:51 am
gmab
Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at Sanford C. Bernstein from a "strong sell" rating to a "hold" rating.
Low
Report
Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at Sanford C. Bernstein from a "strong sell" rating to a "hold" rating.
12/16
01:24 pm
gmab
Antibody Discovery Market Industry Forecast Report 2024-2035, Featuring Ablexis, ChemPartner, Creative Biolabs, GenScript, Genmab, Harbour BioMed, MabSilico, Nona Biosciences, WuXi Biologics and More [Yahoo! Finance]
Low
Report
Antibody Discovery Market Industry Forecast Report 2024-2035, Featuring Ablexis, ChemPartner, Creative Biolabs, GenScript, Genmab, Harbour BioMed, MabSilico, Nona Biosciences, WuXi Biologics and More [Yahoo! Finance]
12/16
07:46 am
gmab
FairJourney Biologics Establishes Scientific Advisory Board [Yahoo! Finance]
Low
Report
FairJourney Biologics Establishes Scientific Advisory Board [Yahoo! Finance]
12/13
03:12 pm
gmab
Genmab A/S: Circling Back On This Complicated Story [Seeking Alpha]
Low
Report
Genmab A/S: Circling Back On This Complicated Story [Seeking Alpha]
12/11
08:28 am
gmab
Genmab to Hold 2024 R&D Update and ASH Data Review Meeting [Yahoo! Finance]
Low
Report
Genmab to Hold 2024 R&D Update and ASH Data Review Meeting [Yahoo! Finance]
12/10
08:20 am
gmab
City of Hope Reports Novel Immunotherapy in Clinical Trial Shows Promise for Patients With Relapsed or Difficult to Treat Chronic Lymphocytic Leukemia (CLL) [Yahoo! Finance]
Low
Report
City of Hope Reports Novel Immunotherapy in Clinical Trial Shows Promise for Patients With Relapsed or Difficult to Treat Chronic Lymphocytic Leukemia (CLL) [Yahoo! Finance]
12/9
12:07 pm
gmab
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) [Yahoo! Finance]
Low
Report
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) [Yahoo! Finance]
12/9
12:00 pm
gmab
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Low
Report
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
12/8
11:07 am
gmab
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis [Yahoo! Finance]
Low
Report
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis [Yahoo! Finance]
12/8
11:00 am
gmab
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
Low
Report
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
12/8
08:13 am
gmab
Genmab Is Too Attractive To Ignore [Seeking Alpha]
Low
Report
Genmab Is Too Attractive To Ignore [Seeking Alpha]
12/7
07:03 pm
gmab
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) [Yahoo! Finance]
Low
Report
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) [Yahoo! Finance]
12/7
07:00 pm
gmab
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Low
Report
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
12/2
03:00 pm
gmab
Why Is Genmab A/S (GMAB) Among the Best High Growth Healthcare Stocks to Invest In Now? [Yahoo! Finance]
Low
Report
Why Is Genmab A/S (GMAB) Among the Best High Growth Healthcare Stocks to Invest In Now? [Yahoo! Finance]
11/25
11:07 am
gmab
Genmab to Present at Citi's Global Healthcare Conference [Yahoo! Finance]
Low
Report
Genmab to Present at Citi's Global Healthcare Conference [Yahoo! Finance]
11/20
10:12 am
gmab
BioNJ Unveils "Time Off for Clinical Trials" Initiative [Yahoo! Finance]
Low
Report
BioNJ Unveils "Time Off for Clinical Trials" Initiative [Yahoo! Finance]
11/8
10:34 am
gmab
Genmab A/S (NASDAQ: GMAB) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $48.00 price target on the stock, up previously from $46.00.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $48.00 price target on the stock, up previously from $46.00.
11/8
02:21 am
gmab
High Growth Tech Stocks To Watch In November 2024 [Yahoo! Finance]
Low
Report
High Growth Tech Stocks To Watch In November 2024 [Yahoo! Finance]
11/6
11:10 am
gmab
Genmab Announces Financial Results for the First Nine Months of 2024 [Yahoo! Finance]
Low
Report
Genmab Announces Financial Results for the First Nine Months of 2024 [Yahoo! Finance]
11/6
11:01 am
gmab
Genmab Announces Financial Results for the First Nine Months of 2024
Low
Report
Genmab Announces Financial Results for the First Nine Months of 2024
11/5
12:13 pm
gmab
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting [Yahoo! Finance]
Low
Report
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting [Yahoo! Finance]
11/5
12:00 pm
gmab
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
Low
Report
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
10/16
11:52 am
gmab
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock? [Yahoo! Finance]
Low
Report
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock? [Yahoo! Finance]
10/16
08:31 am
gmab
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
10/15
11:54 am
gmab
Is Genmab (GMAB) Stock Undervalued Right Now? [Yahoo! Finance]
Low
Report
Is Genmab (GMAB) Stock Undervalued Right Now? [Yahoo! Finance]